Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218543 · ClinicalTrials.gov registry record · Phase 2
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 2 study of Cocaine-Related Disorders and Attention Deficit Disorder With Hyperactivity, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00218543 is a Phase 2 study of Cocaine-Related Disorders and Attention Deficit Disorder With Hyperactivity that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 20 participants, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00218543, a Phase 2 study of Cocaine-Related Disorders and Attention Deficit Disorder With Hyperactivity, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD. Rates of cocaine abuse in adults with ADHD are significantly higher than they are in adults who do not have ADHD. Some clinicians suggest that adults with ADHD may abuse cocaine in order to self-medicate their ADHD symptoms. Atomoxetine is a drug that has been effective in treating ADHD. This study will evaluate the effectiveness of atomoxetine in reducing cocaine use in people with ADHD who abuse cocaine.
Conditions Studied
Interventions
- DRUG Atomoxetine
Study Locations (1)
New York
- Research Foundation for Mental Hygiene, Inc. - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218543
The ClinicalTrials.gov registry entry for NCT00218543 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (69% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Atomoxetine is the first listed.
NCT00218543 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00218543 about?
NCT00218543 is a clinical study titled "Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)". Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD. Rates of cocaine abuse in adults with ADHD are significantly higher than they are in adults who do not have ADHD. ...
What is the current status of trial NCT00218543?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2004-06. Estimated completion is 2007-03.
What conditions does trial NCT00218543 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders, Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT00218543?
The interventions under investigation include: Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00218543?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00218543 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
COMPLETED · Phase 2
-
Pharmacological Modulation of Cocaine Effects - 1
COMPLETED · Phase 2
-
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3
COMPLETED · Phase 2
-
Risperidone Treatment in Dually-Diagnosed Individuals - 2
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Evaluation of Benztropine for Cocaine Craving - 2
COMPLETED · Phase 2
Explore more on PlainTrial
Cocaine-Related Disorders
All registered trials for this condition
Attention Deficit Disorder With Hyperactivity
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.